# A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

> **NCT05378763** · PHASE3 · SUSPENDED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 268 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Poziotinib
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05378763
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-05-12
- **Primary completion:** 2027-12-25
- **Final completion:** 2028-12-25
- **Target enrollment:** 268 (ESTIMATED)
- **Why stopped:** The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05378763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05378763, "A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05378763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*